Karin Ajmani Net Worth

The estimated Net Worth of Karin Ajmani is at least $30.5 Million dollars as of 19 February 2020. Karin Ajmani owns over 490,519 units of Progyny Inc stock worth over $25,844,024 and over the last 5 years Karin sold PGNY stock worth over $4,692,517.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Karin Ajmani PGNY stock SEC Form 4 insiders trading

Karin has made over 3 trades of the Progyny Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Karin exercised 490,519 units of PGNY stock worth $426,752 on 19 February 2020.

The largest trade Karin's ever made was exercising 490,519 units of Progyny Inc stock on 19 February 2020 worth over $426,752. On average, Karin trades about 379,508 units every 39 days since 2019. As of 19 February 2020 Karin still owns at least 1,128,560 units of Progyny Inc stock.

You can see the complete history of Karin Ajmani stock trades at the bottom of the page.

What's Karin Ajmani's mailing address?

Karin's mailing address filed with the SEC is C/O PROGYNY, INC., 1359 BROADWAY, 2ND FL, NEW YORK, NY, 10018.

Insiders trading at Progyny Inc

Over the last 5 years, insiders at Progyny Inc have traded over $949,717,514 worth of Progyny Inc stock and bought 76,923 units worth $999,999 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Plc Gsk, and Gp A, Llcbonderman Davidcou.... On average, Progyny Inc executives and independent directors trade stock every 4 days with the average trade being worth of $2,005,422. The most recent stock trade was executed by Michael E Sturmer on 16 July 2024, trading 9,030 units of PGNY stock currently worth $270,900.

What does Progyny Inc do?

progyny is the leading fertility benefits company that combines service, science, technology and data to provide fertility solutions for self-insured employers. progyny’s approach offers members a comprehensive value based treatment plan that is based on the latest medical science and technology. the benefit plans are designed to improve outcomes, shorten time to pregnancy and reduce total fertility-related costs. progyny supports all fertility solutions to include ivf, iui, embryo banking, egg freezing, adoption and surrogacy.

Complete history of Karin Ajmani stock trades at Progyny Inc

Progyny Inc executives and stock owners

Progyny Inc executives and other stock owners filed with the SEC include:

• David Schlanger,
  Chief Executive Officer, Director
• Peter Anevski,
  President, Chief Operating Officer
• David J. Schlanger,
  Exec. Chairman
• Peter Anevski,
  Chief Exec. Officer
• Mark S. Livingston,
  Chief Financial Officer
• Jennifer Bealer,
  Exec. VP, Gen. Counsel & Sec.
• Jeffrey Park,
  Independent Director
• Cheryl Scott,
  Independent Director
• Kevin Gordon,
  Independent Director
• Beth Seidenberg,
  Independent Chairman of the Board of Directors
• Norman Payson,
  Independent Director
• Frederick Cohen,
  Independent Director
• Roger Holstein,
  Director
• Malissia Clinton,
  Director
• Lisa Greenbaum,
  Executive Vice President, Chief Client Officer
• Jennifer Bealer,
  Executive Vice President, General Counsel
• Mark Livingston,
  Chief Financial Officer, Principal Accounting Officer
• Julie Stadlbauer,
  Exec. VP of Strategic Sales & Partnerships
• Michael Sturmer,
  Pres
• Cassandra Pratt,
  Sr. VP of People
• Risa Fisher,
  Exec. VP of Marketing & Communication
• James Hart,
  VP of Investor Relations
• Fred E Cohen,
  Director
• Xiii Associates, Llc Kpcb,
  10% owner
• Karin Ajmani,
  EVP, Chief of Strategic Dev.
• Perkins Caufield & Byers Xi...,
  
• Plc Gsk,
  10% owner
• Group Holdings (Sbs) Adviso...,
  
• Lloyd H Dean,
  Director
• Gp A, Llcbonderman Davidcou...,
  
• Allison Swartz,
  EVP, GC
• Michael E Sturmer,
  PRESIDENT